Search by Drug Name or NDC
NDC 49281-0422-50 FLUZONE QUADRIVALENT NORTHERN HEMISPHERE 15; 15; 15; 15 ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL Details
FLUZONE QUADRIVALENT NORTHERN HEMISPHERE 15; 15; 15; 15 ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL
FLUZONE QUADRIVALENT NORTHERN HEMISPHERE is a INTRAMUSCULAR INJECTION, SUSPENSION in the VACCINE category. It is labeled and distributed by Sanofi Pasteur Inc.. The primary component is INFLUENZA A VIRUS A/DARWIN/9/2021 SAN-010 (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED); INFLUENZA A VIRUS A/VICTORIA/2570/2019 IVR-215 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED); INFLUENZA B VIRUS B/MICHIGAN/01/2021 ANTIGEN (FORMALDEHYDE INACTIVATED); INFLUEN.
MedlinePlus Drug Summary
Why get vaccinated? Influenza vaccine can prevent influenza (flu). Flu is a contagious disease that spreads around the United States every year, usually between October and May. Anyone can get the flu, but it is more dangerous for some people. Infants and young children, people 65 years of age and older, pregnant people, and people with certain health conditions or a weakened immune system are at greatest risk of flu complications. Pneumonia, bronchitis, sinus infections and ear infections are examples of flu-related complications. If you have a medical condition, such as heart disease, cancer or diabetes, flu can make it worse. Flu can cause fever and chills, sore throat, muscle aches, fatigue, cough, headache, and runny or stuffy nose. Some people may have vomiting and diarrhea, though this is more common in children than adults. Each year thousands of people in the United States die from flu, and many more are hospitalized. Flu vaccine prevents millions of illnesses and flu-related visits to the doctor each year.
Related Packages: 49281-0422-50Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Influenza Vaccine, Inactivated or Recombinant
Product Information
| NDC | 49281-0422 |
|---|---|
| Product ID | 49281-422_630e666a-9196-4d8c-9b96-7ee44f4daf5f |
| Associated GPIs | |
| GCN Sequence Number | 083293 |
| GCN Sequence Number Description | flu vacc qs2022-23(6mos up)/PF VIAL 60MCG/.5ML INTRAMUSC |
| HIC3 | W7C |
| HIC3 Description | INFLUENZA VIRUS VACCINES |
| GCN | 52204 |
| HICL Sequence Number | 047932 |
| HICL Sequence Number Description | INFLUENZA VIRUS VACCINE QUADRIVAL 2022-2023(6 MOS AND UP)/PF |
| Brand/Generic | Brand |
| Proprietary Name | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | INFLUENZA A VIRUS A/Victoria/2570/2019 IVR-215 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/DARWIN/9/2021 SAN-010 (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA B VIRUS B/PHUKET/3073/2013 ANTIGEN (FORMALDEHYDE INACTIVATED), and INF |
| Product Type | VACCINE |
| Dosage Form | INJECTION, SUSPENSION |
| Route | INTRAMUSCULAR |
| Active Ingredient Strength | 15; 15; 15; 15 |
| Active Ingredient Units | ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL |
| Substance Name | INFLUENZA A VIRUS A/DARWIN/9/2021 SAN-010 (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED); INFLUENZA A VIRUS A/VICTORIA/2570/2019 IVR-215 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED); INFLUENZA B VIRUS B/MICHIGAN/01/2021 ANTIGEN (FORMALDEHYDE INACTIVATED); INFLUEN |
| Labeler Name | Sanofi Pasteur Inc. |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA103914 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 49281-0422-50 (49281042250)
| NDC Package Code | 49281-422-50 |
|---|---|
| Billing NDC | 49281042250 |
| Package | 10 SYRINGE, GLASS in 1 PACKAGE (49281-422-50) / .5 mL in 1 SYRINGE, GLASS (49281-422-88) |
| Marketing Start Date | 2022-07-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |